Sign In
Buy CRVS
$11.60
-0.0900 (-0.770%)
At Close: Jun 03, 2026
Analysts Offer Insights on Healthcare Companies: Dynavax (DVAX), Proteostasis Therapeutics (PTI) and Inmune Bio (INMB)
11:14am, Thursday, 12'th Mar 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAX), Proteostasis Therapeutics (PTI) and Inmune
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAX
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
12:00am, Thursday, 12'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
Analysts Offer Insights on Healthcare Companies: ChemoCentryx (CCXI), Crinetics Pharmaceuticals (CRNX) and Trillium Therapeutics (TRIL)
11:14am, Wednesday, 11'th Mar 2020
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ChemoCentryx (CCXI), Crinetics Pharmaceuticals (CRNX) and
Companies in the
Healthcare sector have received a lot of coverage today as analysts
weigh in on ChemoCentryx (
CCXI
–
Research Report
), Crinetics Pharmaceuticals (
CRNX
–
Research Report
) and T
Edited Transcript of CRVS earnings conference call or presentation 5-Mar-20 9:30pm GMT
09:14pm, Tuesday, 10'th Mar 2020
Q4 2019 Corvus Pharmaceuticals Inc Earnings Call
Jefferies likes United Therapeutics in premarket analyst action
11:56am, Tuesday, 10'th Mar 2020
Appili Therapeutics (APLI CN) initiated with Buy rating and C$4 (602% upside) price target at Maxim Group.Aphria (NYSE:APHA) initiated with Hold rating and C$4.50 (7% upside) price target at Stifel. S
Mizuho Securities Remains a Buy on Arcus Biosciences (RCUS)
03:44am, Friday, 06'th Mar 2020
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Arcus Biosciences (RCUS) yesterday and set a price target of $22.00. The company's
Mizuho Securities Remains a Buy on Arcus Biosciences (RCUS)
03:44am, Friday, 06'th Mar 2020
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) yesterday and set a
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
09:05pm, Thursday, 05'th Mar 2020
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel b
The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19
01:05pm, Thursday, 05'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences In
Fate Therapeutics (FATE) Received its Third Buy in a Row
01:29am, Tuesday, 03'rd Mar 2020
After Wells Fargo and Wedbush gave Fate Therapeutics (NASDAQ: FATE) a Buy rating last month, the company received another Buy, this time from Mizuho
Fate Therapeutics (FATE) Received its Third Buy in a Row
01:29am, Tuesday, 03'rd Mar 2020
After Wells Fargo and Wedbush gave Fate Therapeutics (NASDAQ: FATE) a Buy rating last month, the company received another Buy,
ORIC Pharma Plans IPO to Test Therapies for Drug-Resistant Cancers
10:18pm, Monday, 02'nd Mar 2020
With one investigational cancer drug in Phase 1 testing and a second one approaching the clinic, ORIC Pharmaceuticals is looking to tap the public markets
Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter 2019 Financial Results on March 5, 2020
09:01pm, Friday, 28'th Feb 2020
BURLINGAME, Calif., Feb. 28, 2020 -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
